Publicatie

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT) : a randomised, double-blind, placebo-controlled phase 3 trial